Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants
Recruitment status was Recruiting
VLBW infants are at risk of developing retinopathy of prematurity (ROP). In the first phase of ROP there is a down-regulation of retinal VEGF-expression because of postnatal relative hyperoxia, followed by an upregulation of VEGF mediated through retinal hypoxia, which leads to pathologic vessel formation. VEGF acts through binding to the specific receptor FLT-1, the soluble form sFLT-1 is a specific antagonist of VEGF action. Erythropoietin, given to VLBW infants to prevent anemia, may stimulate VEGF-production in neuronal cells. Currently, there are no data published about VEGF urine-levels in VLBW infants and it is not known, if urine VEGF-levels may serve as a non-invasive marker of ROP-risk. Further shall be investigated, if erythropoietin-therapy increases urine VEGF-levels and if there is a correlation with ROP-development.
Infant, Very Low Birth Weight
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
- Development of ROP [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Urine samples that are centrifugated to get rid of any cells where stored at -80°C until ELISA is done.
|Study Start Date:||August 2008|
|Estimated Study Completion Date:||December 2010|
|Estimated Primary Completion Date:||February 2010 (Final data collection date for primary outcome measure)|
VLBW infants with erythropoietin therapy
VLBW infants without erythropoietin therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00799721
|Contact: Anke Reinhold, Doctorfirstname.lastname@example.org|
|Contact: Anja Pohl-Schickinger, Doctoremail@example.com|
|Berlin, Germany, 13353|
|Contact: Anke Reinhold, Doctor firstname.lastname@example.org|